Clinical trials for Mantle cell lymphoma
36 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPhase 2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPhase 2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGN/ANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPhase 2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPhase 3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines · PI: Study Director
- RECRUITINGNCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company · PI: Bristol-Myers Squibb
- RECRUITINGPhase 2NCT06522386GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center · PI: Michael Wang, MD, MS
- RECRUITINGPhase 2NCT06263491Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsM.D. Anderson Cancer Center · PI: Preetesh Jain, MBBS, MD, DM, PhD
- RECRUITINGPhase 3NCT06363994A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLInnoCare Pharma Inc.
- RECRUITINGPhase 2NCT05635162Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaUniversity College, London
- ACTIVE NOT RECRUITINGPhase 1NCT06192888A Study of Glofitamab and Lenalidomide in People With Mantle Cell LymphomaMemorial Sloan Kettering Cancer Center · PI: Anita Kumar, MD
- RECRUITINGPhase 2NCT05910801Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaAcademic and Community Cancer Research United · PI: Yucai Wang
- ACTIVE NOT RECRUITINGPhase 2NCT05951959A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaAstraZeneca
- ACTIVE NOT RECRUITINGPhase 2NCT05864742Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaPeter MacCallum Cancer Centre, Australia
- RECRUITINGPHASE1, PHASE2NCT05861050Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaCity of Hope Medical Center · PI: Tycel J Phillips
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05471843Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell LymphomaBeiGene
- RECRUITINGPhase 2NCT05249959Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.Fondazione Italiana Linfomi - ETS · PI: Marco Ladetto
- ACTIVE NOT RECRUITINGPhase 2NCT04802590Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell LymphomaThe Lymphoma Academic Research Organisation · PI: Steven Le Gouill
- ACTIVE NOT RECRUITINGPhase 2NCT05214183Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell LymphomaNordic Lymphoma Group · PI: Mats Jerkeman
- RECRUITINGPhase 2NCT04626791Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaAcademic and Community Cancer Research United · PI: Stephen D Smith
- RECRUITINGPHASE1, PHASE2NCT04855695Avo In R/R And Previously Untreated MCLAustin I Kim · PI: Austin I Kim, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04765111Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center · PI: Luhua (Michael) Wang
- ACTIVE NOT RECRUITINGPhase 2NCT04624958Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCLSun Yat-sen University · PI: Qingqing Cai, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03282396Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell LymphomaM.D. Anderson Cancer Center · PI: Luhua (Michael) Wang
- ACTIVE NOT RECRUITINGPhase 2NCT04115631A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaECOG-ACRIN Cancer Research Group · PI: Nina D Wagner-Johnston
- RECRUITINGPhase 2NCT04054167Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaM.D. Anderson Cancer Center · PI: Bouthaina S Dabaja
- ACTIVE NOT RECRUITINGPhase 2NCT03872180Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaEmory University · PI: Jonathon B. Cohen, MD, MS
- ACTIVE NOT RECRUITINGPhase 2NCT03478514Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaAlliance Foundation Trials, LLC. · PI: Evanthia Galanis, MD
- ACTIVE NOT RECRUITINGPhase 3NCT03267433Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionECOG-ACRIN Cancer Research Group · PI: Timothy S Fenske
- ACTIVE NOT RECRUITINGPhase 3NCT02972840A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLAcerta Pharma BV
- RECRUITINGPhase 3NCT02858258ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaProf. Dr. M. Dreyling (co-chairman) · PI: Martin Dreyling, Prof.
- ACTIVE NOT RECRUITINGPhase 2NCT02682641Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · PI: Eva Giné, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02465060Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI) · PI: Keith T Flaherty
- ACTIVE NOT RECRUITINGPhase 2NCT02213926An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaAcerta Pharma BV · PI: Acerta Pharma
- ACTIVE NOT RECRUITINGPhase 2NCT01880567Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaM.D. Anderson Cancer Center · PI: Preetesh Jain